Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Xspray Pharma AB (XSPRAY) Stock Price & Analysis

3 Followers

XSPRAY Stock Chart & Stats

kr 12.04kr 0.34(2.91%)
At close: 5:30 PM GMT+1
kr 10kr 12.5kr 15Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
SEK 11.52 - SEK 12.04
52-Week Range
SEK 9.06 - SEK 35.15
Previous Close
SEK 11.70
Volume
N/A
Average Volume (3M)
63.56K
Market Cap
SEK 551.93M
Enterprise Value
SEK 645.43M
Total Cash (Recent Filing)
SEK 179.91M
Total Debt (Recent Filing)
SEK 147.30M
Price to Earnings (P/E)
―
Beta
0.94
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

HyNap Formulation Platform

HyNap gives Xspray a focused platform for developing differentiated or bioequivalent versions of established medicines. Potential improvements in bioavailability and reduced food effects could support licensing, partnering, and commercialization opportunities across specialty pharmaceutical markets.

Moderate Leverage

Substantial equity relative to debt provides a stronger financial foundation than the company’s profitability profile alone would suggest. Moderate leverage can preserve financing flexibility and reduce balance-sheet pressure while Xspray advances products toward regulatory and commercial milestones.

Improving Loss Trend

Although Xspray remains unprofitable, the reduction in net losses from the 2024 trough indicates some improvement in financial performance. If sustained, lower losses could extend the company’s operating runway and reduce the funding burden before meaningful commercialization begins.

Bears Say

No Commercial Revenue

The absence of reported revenue means Xspray has not yet demonstrated a recurring commercial income stream from its products or technology. This leaves future financial performance dependent on successful development, regulatory progress, partnerships, and eventual market adoption.

Persistent Cash Burn

Sustained negative operating and free cash flow shows that current activities consume cash rather than fund themselves. Continued outflows can limit investment capacity and require additional financing, particularly if development spending remains elevated before products generate revenue.

Rising Leverage And Funding Reliance

Debt has risen from very low levels in earlier years even as Xspray continues to report losses and cash burn. Greater reliance on external capital increases sensitivity to financing conditions and may constrain strategic flexibility if funding becomes more difficult or costly.

Xspray Pharma AB News

XSPRAY FAQ

What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr 9.06 and its highest was kr 35.15 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr 551.93M.
When is Xspray Pharma AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr 0.868 earnings per share for the quarter.
Is Xspray Pharma AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr 0.868 in its last earnings report. Following the earnings report the stock price went up 2.906%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology